Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191599 | 0.94 | TLR8 (0.35) | TLR8TLR7TSHRP2RY1KCNA5 | |
| SCHEMBL22024146 | 0.94 | NAPRT (0.34) | TLR8KCNA5KCNH2NAPRT | |
| SCHEMBL21191754 | 0.92 | TLR8 (0.36) | TLR8TLR7TSHRP2RY1 | |
| SCHEMBL21191591 | 0.92 | TLR8 (0.36) | TLR8TLR7TSHRP2RY1KCNA5 | |
| SCHEMBL22140273 | 0.87 | KCNA5 (0.33) | TLR8KCNA5KCNH2NAPRT | |
| SCHEMBL22023795 | 0.84 | CNR1 (0.35) | TLR8TLR7TSHRP2RY1KCNA5 | |
| SCHEMBL25736987 | 0.81 | TLR8 (0.38) | TLR8TLR7P2RY1NAPRT | |
| SCHEMBL22624021 | 0.79 | TLR8 (0.34) | TLR8TLR7TSHR | |
| SCHEMBL22624032 | 0.75 | P2RY1 (0.39) | TLR8TLR7TSHRP2RY1KCNH2 | |
| SCHEMBL22023658 | 0.73 | NAPRT (0.36) | KCNA5KCNH2NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | TLR8 2663/4885TLR7 727/4885TSHR 3380/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | TLR8 2663/4885TLR7 727/4885TSHR 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.